Indoco Remedies posted lower than expected numbers for 4QFY2017. In sales, the company posted revenues of `266cr (`311cr expected) v/s. `255cr in 4QFY2016, growth of 4.2% yoy. The formulation business posted sales of `251.6cr, up 3.3% yoy, while API at `12.0cr was down 4.7% yoy. The domestic formulation at `130.1cr recorded a yoy de-growt..